OverviewSuggest Edit
Pfenex is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins. The Company has developed a high-quality protein production and bioanalytic technology platform approach that allows them to create biosimilars in a highly efficient manner.
Pfenex's patented protein production platform, Pfenex Expression Technology, enables its ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enable the rapid delivery of protein products into clinical development and commercialization.
| Type | Public | |
| Founded | 2009 | |
| HQ | San Diego, CA, US | Map |
| Website | pfenex.com | |
| Employee Ratings | More |
Recent NewsAll News
- Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.
- Pfenex to Announce Second Quarter Financial Results on August 6
- Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
Key People/Management at Pfenex
Martin Brenner
Shawn Scranton
Patrick K. Lucy
Eef Schimmelpennink
Jason Grenfell-Gardner
Pfenex Office Locations
Pfenex Financials and Metrics
Pfenex Revenue
| USD | |
|---|---|
Revenue (Q2, 2020) | 781.0k |
Gross profit (Q2, 2020) | 101.0k |
Gross profit margin (Q2, 2020), % | 12.9% |
Net income (Q2, 2020) | (10.3m) |
EBIT (Q2, 2020) | (10.3m) |
Market capitalization (5-Oct-2020) | 437.3m |
Closing stock price (5-Oct-2020) | 12.8 |
Cash (30-Jun-2020) | 61.0m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.3m | 2.8m | 2.0m | 2.3m | 2.1m | 2.8m | 3.1m | 48.8m | 2.8m | 3.0m | 5.0m | 3.7m | 4.2m | 3.6m | 10.4m | 2.8m | 15.2m | 682.0k | 781.0k |
Cost of goods sold | 2.5m | 1.6m | 1.3m | 921.0k | 682.0k | 1.3m | 1.4m | 1.3m | 810.0k | 905.0k | 1.8m | 1.5m | 924.0k | 1.5m | 1.6m | 1.1m | 1.1m | 340.0k | 680.0k |
Gross profit | 722.0k | 1.2m | 667.0k | 1.4m | 1.4m | 1.5m | 1.7m | 47.5m | 2.0m | 2.1m | 3.3m | 2.2m | 3.3m | 2.1m | 8.8m | 1.7m | 14.1m | 342.0k | 101.0k |
Gross profit Margin, % | 22% | 44% | 34% | 60% | 67% | 54% | 54% | 97% | 71% | 70% | 65% | 59% | 78% | 59% | 85% | 60% | 93% | 50% | 13% |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 3.9m | 51.5m | 92.0m | 123.0m | 115.9m | 96.5m | 89.6m | 93.6m | 70.2m | 59.9m | 48.4m | 47.1m | 80.2m | 67.8m | 45.8m | 41.6m | 32.5m | 65.6m | 61.0m |
Accounts Receivable | 1.4m | 1.8m | |||||||||||||||||
Prepaid Expenses | 1.5m | 426.0k | 2.1m | 2.3m | 2.0m | 2.1m | 3.1m | 2.3m | 1.8m | 1.3m | 1.7m | 1.6m | 1.7m | 2.0m | 2.1m | 1.7m | 2.4m | ||
Inventories | 18.0k | 24.0k | 21.0k | 31.0k | 25.0k |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.7m) | (6.2m) | (6.0m) | (12.0m) | (19.5m) | (8.2m) | (18.4m) | 16.1m | (10.0m) | (22.4m) | (31.2m) | (11.0m) | (22.1m) | (32.8m) | (3.7m) | (11.3m) | (8.2m) | (10.2m) | (20.5m) |
Depreciation and Amortization | 498.0k | 746.0k | 259.0k | 523.0k | 792.0k | 282.0k | 575.0k | 886.0k | 319.0k | 657.0k | 1.0m | 407.0k | 824.0k | 1.2m | 444.0k | 892.0k | 1.4m | 466.0k | 957.0k |
Inventories | 8.0k | 2.0k | 2.0k | (8.0k) | (2.0k) | ||||||||||||||
Accounts Payable | (677.0k) | (324.0k) | 685.0k | 598.0k | 273.0k | 202.0k | 562.0k | 1.0m | (79.0k) | 475.0k | 307.0k | (333.0k) | 630.0k | (560.0k) | (822.0k) | (1.5m) | 100.0k | (275.0k) | 1.5m |
| USD | Q2, 2014 |
|---|---|
Financial Leverage | -0.3 x |
Pfenex Cybersecurity Score
Pfenex Environment, Social & Governance (ESG) Ratings
Pfenex Online and Social Media Presence
4.09k Twitter followers
Pfenex has 4.09k Twitter Followers. The number of followers has decreased 0.2% month over month and decreased 1.2% quarter over quarter
Pfenex's Trends
Pfenex News and Updates
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.
Pfenex to Announce Second Quarter Financial Results on August 6
Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
Pfenex Blogs
Pfenex Reports Second Quarter 2020 Results and Provides Business Update
Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
Pfenex Frequently Asked Questions
When was Pfenex founded?
Pfenex was founded in 2009.
Who are Pfenex key executives?
Pfenex's key executives are Martin Brenner, Shawn Scranton and Patrick K. Lucy.
How many employees does Pfenex have?
Pfenex has 83 employees.
What is Pfenex revenue?
Latest Pfenex annual revenue is $50.3 m.
What is Pfenex revenue per employee?
Latest Pfenex revenue per employee is $606.3 k.
Who are Pfenex competitors?
Competitors of Pfenex include Frequency Therapeutics, U.S. Stem Cell and Biohaven Pharmaceutical.
Where is Pfenex headquarters?
Pfenex headquarters is located at 10790 Roselle St, San Diego.
Where are Pfenex offices?
Pfenex has an office in San Diego.
How many offices does Pfenex have?
Pfenex has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies